Global languages
2009-10-23
Regulatory

CellaVision AB - Interim report for the period January 1 - September 30, 2009

  •    Net sales increased by 12% to SEK 69.6 million (62.1), of which the third quarter accounted for SEK 27.0 million (20.8).
  •    The operating profit for the period was SEK 7.3 million (6.3), and for the third quarter SEK 5.5 million (3.6).
  •    Earnings per share for the period amounted to SEK 0.28 (0.25), and for the third quarter SEK 0.22 (0.14).
  •    Cash and cash equivalents amounted to SEK 11.9 million (11.3) by the end of the period.
  •    The new analyzer CellaVision® DM1200 became commercially available in Europe and Canada and was successfully introduced on the market. The first substantial order was taken in Europe.
    •  
     
      CellaVision in summary
     
     
     
     
      (MSEK)
     
     
    Q3 2009
    Q3 2008
    Jan-Sep 2009
    Jan-Sep 2008
    Full year 2008
      Net sales
    27.0
    20.8
    69.6
    62.1
    100.4
      Gross profit
    20.1
    16.6
    51.0
    42.4
    63.5
      Operating result
    5.5
    3.6
    7.3
    6.3
    13.4
      Net result
    5.4
    3.4
    6.8
    6.0
    13.1
      Cash flow
    2.6
    -5.6
    -7.7
    -5.0
    3.3
     
     
    CEO's comment
    "Our new product CellaVision DM1200 is now commercially available in both Europe and Canada which will be beneficial for sales," says Yvonne Mårtensson, CEO of CellaVision. "We got the first substantial order from our distributor Sysmex Europe. The order comprised close to twenty analyzers, which indicates that adapting our product to the needs of medium-sized hospitals was strategically correct."
     
    "We show solid increase in terms of both revenue and results during the third quarter despite the global financial crisis, and we continue to show a strong gross margin."
     
    "During the quarter our own sales organizations have taken orders from important customers in the USA, Canada, Japan, as well as the Nordic region, and we continue to work hard to strengthen our position in each of those markets."
     
    Yvonne Mårtensson
    CEO CellaVision AB
     
     
    For further information, please contact:   
    Yvonne Mårtensson, CEO. Phone: +46 708 33 77 82, e-mail: yvonne.martensson@cellavision.com
    Johan Wennerholm, CFO. Phone: +46 708 33 81 68, e-mail: johan.wennerholm@cellavision.com

    Attachments

    CellaVision AB - Interim report for the period January 1 - Sep 30, 2009

    Share